Handelsavisen
prelaunch
NT
NTH.MC BME Madrid Miscellaneous Specialty Retailers

Naturhouse Health SA

€464,90
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
13,83 %
Op margin
28,2 %
ROE
56,9 %
Net margin
21,2 %
Debt / equity
0,14
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Naturhouse Health SA operates in the retail sector, specializing in health and wellness products, and generates revenue primarily through the sale of these products to consumers.

Business. Naturhouse Health SA (NTH.MC) is a miscellaneous specialty retailer headquartered in Spain and listed on the BME (Madrid) exchange. The company operates within the Consumer Cyclicals sector, generating revenue primarily through product sales. Specific details regarding operating segments and geographic breakdowns are not provided in the available data.

Classification92 %
SectorConsumer Cyclicals
Business sectorRetailers
IndustryMiscellaneous Specialty Retailers
ActivityRetailers
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
56,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NTH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary · THIS SECTOR+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NTH.MC. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Naturhouse Health SA (NTH.MC) is a miscellaneous specialty retailer headquartered in Spain and listed on the BME (Madrid) exchange. The company operates within the Consumer Cyclicals sector, generating revenue primarily through product sales. Specific details regarding operating segments and geographic breakdowns are not provided in the available data.

    Classification92 %
    SectorConsumer Cyclicals
    Business sectorRetailers
    IndustryMiscellaneous Specialty Retailers
    ActivityRetailers
    AI synthesis
    GENERATED

    Naturhouse Health SA maintains a strong liquidity position, with a current ratio of 1.65, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score further supports this, showing a low liquidity risk. However, the company's free cash flow is negative at -6.522 million EUR, which may indicate that capital expenditures and other operational costs are outpacing cash inflows.

    In terms of profitability, Naturhouse Health SA demonstrates a return on equity of 56.86% and a return on assets of 30.19%, both of which are strong indicators of efficient use of equity and assets to generate profit. The company's operating income of 13.418 million EUR and net income of 10.094 million EUR suggest a healthy margin, although the exact comparison to industry medians is not provided in the available data.

    The company's revenue is not segmented by product or geographic region in the provided data, so the extent of revenue concentration in specific segments or regions cannot be determined. However, the company's operations are likely concentrated in the European market, given the EUR financial reporting and the company's listing on the Madrid Stock Exchange.

    Looking at the growth trajectory, the company's revenue for the latest period is reported at 47.629 million EUR, and the analyst estimate for the last actual revenue is 49.425 million EUR, suggesting a slight positive growth trend. The outlook for the current and next fiscal years is not explicitly provided, but the company's strong profitability and liquidity position may support continued growth.

    The risk assessment indicates a low risk of dilution and no immediate filing-based liquidity or dilution flags were detected. The company's debt to equity ratio of 0.14 suggests a conservative capital structure with minimal long-term debt, which reduces financial risk.

    Recent events, such as filings or transcripts, are not detailed in the provided data, so no specific recent developments can be cited. However, the company's financial health and low risk profile suggest that it is well-positioned to navigate potential market challenges.

    Key takeaways
    • Naturhouse Health SA has a strong liquidity position with a current ratio of 1.65.
    • The company demonstrates high profitability with a return on equity of 56.86% and a return on assets of 30.19%.
    • The company's capital structure is conservative, with a low debt to equity ratio of 0.14.
    • The company's free cash flow is negative, indicating that capital expenditures and operational costs are outpacing cash inflows.
    • The company has a low risk of dilution and no immediate filing-based liquidity or dilution flags were detected.
    • "margin_outlook_rationale": "The company's strong profitability, as indicated by its high return on equity and return on assets, suggests that margins are likely to remain stable or improve in the near term.",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    €464,90
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    €17.8M
    Net cash
    €11.0M
    Current ratio
    1.6
    Debt / equity
    0.1
    ROA
    30.2%
    ROE
    56.9%
    Cash conversion
    120.0%
    CapEx / revenue
    -1.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin28,2 %Best in class
    Net Margin21,2 %Best in class
    ROE56,9 %Best in class
    Capex / Rev-1,0 %Above median
    D/E0,14Above median
    Cash Conv1,20Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Naturhouse Health SA Market data — financials · 2026-05-28
    • Naturhouse Health SA Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NTH.MCCanonical
    BME Madrid · EUR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage